



# Grant of Options and PDMR Dealing

January 5, 2024 7:00 AM EST

RNS Number : 7228Y  
MaxCyte, Inc.  
05 January 2024



## MaxCyte, Inc.

("MaxCyte" or the "Company")

### Grant of Options and PDMR Dealing

**ROCKVILLE, MD, 5 January 2024:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications to support innovative, cell-based research, announces that on 3 January 2024, 400,000 options of common stock in the Company ("Common Stock") were granted to Maher Masoud, President, Chief Executive Officer and Director of the Company pursuant to a pre-agreed arrangement in connection with his appointment as President, Chief Executive Officer and Director of the Company as announced on 12 December 2023.

The options granted vest 12/48th of the total grant on 2 January 2025, and 1/48th of the total shares will vest each month thereafter on the same day of the month. The options granted have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 3 January 2024, being \$4.42 on the Nasdaq Stock Exchange.

#### MaxCyte Contacts:

##### *US IR Adviser*

##### **Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

##### *Nominated Adviser and Joint*

##### **Corporate Broker**

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

##### *UK IR Adviser*

##### **ICR Consilium**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

#### About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our EXPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [Twitter](https://twitter.com/MaxCyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Maher Masoud				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	President, CEO and Director				
b)	Initial notification /Amendment	Initial notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	MaxCyte Inc.				
b)	LEI	54930053YHXULRFCU991				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument  Identification code	Common Stock of \$0.01 each  US57777K1060				
b)	Nature of the transaction	Grant of options of common stock				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>\$4.42</td> <td>400,000</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	\$4.42	400,000
Exercise Price(s)	Volume(s)					
\$4.42	400,000					
d)	Aggregated information  - Aggregated volume  - Price	400,000  \$4.42				

e)	Date of the transaction	January 3, 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHZZGGMMDGGDZZ